A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia.

Trial Profile

A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs ELND 005 (Primary)
  • Indications Down syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Elan Pharma International; Elan Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Apr 2014 This trial is close to completing enrolment, and data are expected in quarter 3, 2014, according to a Transition Therapeutics media release.
    • 29 Jan 2014 Planned End Date changed from 1 Jul 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top